Marinomed Biotech

Marinomed Biotech has filed for court-supervised restructuring proceedings without self-administration. The market‑making contract with Raiffeisen Bank International was terminated with immediate effect, which is expected to result in lower trading liquidity and wider bid‑ask spreads in the short term. Publication of the 2026 half‑year financial report has been postponed indefinitely; the management board is seeking a new market‑making mandate promptly. » Plus sur finanzen.net

Marinomed Biotech reports that the total number of voting rights increased to 1,998,979 as a result of the capital increase of 13 April 2026, effective at the end of April 2026. The new share capital amounts to EUR 1,998,979 and the change has been effective since 16 April 2026. » Plus sur de.investing.com

The management board of Marinomed Biotech has decided on a cash capital increase to cover a short-term funding need of around EUR 2 million. Up to 459,985 new common shares are to be issued; existing shareholders will receive subscription rights at a ratio of 4:1 at a subscription price of EUR 14.00 per share. The subscription period begins on 26 March 2026 and is expected to end on 9 April 2026; unsubscribed shares will be offered in a private placement. An institutional investor has given a binding commitment to subscribe for New Shares in the rump placement in the amount of EUR 1 million. » Plus sur de.investing.com